News Releases

Nov 16, 2022
Biodesix Announces Proposed Public Offering of Common Stock
BOULDER, Colo. --(BUSINESS WIRE)--Nov. 16, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it has commenced an underwritten public offering of $30 million of shares of its common stock, before deducting
Nov 03, 2022
Biodesix Announces Third Quarter 2022 Results and Highlights
Third quarter 2022 core Lung Diagnostic revenue of $9.2 million increased 102% over the comparable period in 2021; U.S. Federal Supply Schedule Contract expands coverage to Veterans Health Administration and Military Health System Medical Centers for its entire Lung Diagnostic portfolio; Conference
Oct 20, 2022
Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022
BOULDER, Colo. --(BUSINESS WIRE)--Oct. 20, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, today announced that it will release financial results for the third quarter ended September 30, 2022 before the open of trading on
Displaying 1 - 10 of 39